Colorectal Cancer Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Colorectal Cancer stocks.

Recent Signals

Date Stock Signal Type
2021-08-02 BNR NR7 Range Contraction
2021-08-02 CHEK Bollinger Band Squeeze Range Contraction
2021-08-02 CHEK Narrow Range Bar Range Contraction
2021-08-02 CHEK Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-08-02 CHEK 1,2,3 Retracement Bearish Bearish Swing Setup
2021-08-02 EXAS Lower Bollinger Band Walk Weakness
2021-08-02 EXAS Calm After Storm Range Contraction
2021-08-02 IDRA Bollinger Band Squeeze Range Contraction
2021-08-02 IDRA NR7 Range Contraction
2021-08-02 IDRA Narrow Range Bar Range Contraction
2021-08-02 INFU Crossed Above 20 DMA Bullish
2021-08-02 INFU 50 DMA Resistance Bearish
2021-08-02 INFU Crossed Above 200 DMA Bullish
2021-08-02 INFU Bollinger Band Squeeze Range Contraction
2021-08-02 INFU Cup with Handle Other
2021-08-02 INFU MACD Bullish Signal Line Cross Bullish
2021-08-02 ISR NR7 Range Contraction
2021-08-02 ISR NR7-2 Range Contraction
2021-08-02 ISR Narrow Range Bar Range Contraction
2021-08-02 MOTS Bollinger Band Squeeze Range Contraction
2021-08-02 MOTS 20 DMA Resistance Bearish
2021-08-02 MOTS Non-ADX 1,2,3,4 Bearish Bearish Swing Setup
2021-08-02 MYGN Bollinger Band Squeeze Range Contraction
2021-08-02 MYGN Bearish Engulfing Bearish
2021-08-02 MYGN 20 DMA Resistance Bearish
2021-08-02 NAVB Lower Bollinger Band Walk Weakness
2021-08-02 REGN Bollinger Band Squeeze Range Contraction
2021-08-02 REGN Cup with Handle Other
2021-08-02 SNY 20 DMA Resistance Bearish
2021-08-02 SNY Pocket Pivot Bullish Swing Setup
2021-08-02 SNY Bollinger Band Squeeze Range Contraction
2021-08-02 TCON Shooting Star Candlestick Bearish
2021-08-02 TCON Doji - Bearish? Reversal

Colorectal Cancer Stocks Recent News

Date Stock Title
Aug 2 SNY Translate Bio Stock Soars on Reports Sanofi Makes Takeover Bid
Aug 2 SNY Translate Bio surges in after hours on report of Sanofi bid (update)
Aug 2 SNY Exclusive-Sanofi offers to buy U.S. biotech, mRNA partner Translate Bio -sources
Aug 2 MYGN Myriad Genetics Q2 2021 Earnings Preview
Aug 2 REGN Doctor on COVID-19: 'People who are vaccinated are still very susceptible to infection'
Aug 2 SNY Doctor on COVID-19: 'People who are vaccinated are still very susceptible to infection'
Aug 2 REGN Regeneron: Rapid Growth Seems To Be On A Pause
Aug 2 REGN Will Eylea & Dupixent Drive Regeneron's (REGN) Q2 Earnings?
Aug 2 SNY Will Eylea & Dupixent Drive Regeneron's (REGN) Q2 Earnings?
Aug 2 MYGN Myriad Genetics launches new version of MyRisk Hereditary Cancer Test
Aug 2 MYGN Myriad Genetics Expands Access to Genetic Testing with Launch of First Polygenic Breast Cancer Risk Assessment Score Validated for Women of All Ancestries
Aug 2 REGN FDA Approves Regeneron - Roche's COVID-19 Antibody Cocktail For Post-Exposure Prophylaxis
Aug 2 BNR Burning Rock Schedules Second Quarter of 2021 Earnings Release on August 31, 2021
Aug 1 MYGN The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Aug 1 AVEO The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Jul 31 SNY Sanofi (SNY) Q2 2021 Earnings Call Transcript
Jul 30 REGN Regeneron Pharmaceuticals (REGN) Long-Term Investor Alert: Contact Johnson Fistel Regarding Investigation
Jul 30 REGN Regeneron wins expanded authorization from FDA for COVID-19 antibody cocktail
Jul 30 REGN FDA okays Regeneron COVID-19 antibody as preventive in high-risk settings
Jul 30 REGN Doctor on Delta variant: ’All of us are extremely concerned’

Colorectal cancer (CRC), also known as bowel cancer and colon cancer, is the development of cancer from the colon or rectum (parts of the large intestine). A cancer is the abnormal growth of cells that have the ability to invade or spread to other parts of the body. Signs and symptoms may include blood in the stool, a change in bowel movements, weight loss, and feeling tired all the time.Most colorectal cancers are due to old age and lifestyle factors, with only a small number of cases due to underlying genetic disorders. Some risk factors include diet, obesity, smoking, and lack of physical activity. Dietary factors that increase the risk include red meat, processed meat, and alcohol. Another risk factor is inflammatory bowel disease, which includes Crohn's disease and ulcerative colitis. Some of the inherited genetic disorders that can cause colorectal cancer include familial adenomatous polyposis and hereditary non-polyposis colon cancer; however, these represent less than 5% of cases. It typically starts as a benign tumor, often in the form of a polyp, which over time becomes cancerous.Bowel cancer may be diagnosed by obtaining a sample of the colon during a sigmoidoscopy or colonoscopy. This is then followed by medical imaging to determine if the disease has spread. Screening is effective for preventing and decreasing deaths from colorectal cancer. Screening, by one of a number of methods, is recommended starting from the age of 50 to 75. During colonoscopy, small polyps may be removed if found. If a large polyp or tumor is found, a biopsy may be performed to check if it is cancerous. Aspirin and other non-steroidal anti-inflammatory drugs decrease the risk. Their general use is not recommended for this purpose, however, due to side effects.Treatments used for colorectal cancer may include some combination of surgery, radiation therapy, chemotherapy and targeted therapy. Cancers that are confined within the wall of the colon may be curable with surgery, while cancer that has spread widely are usually not curable, with management being directed towards improving quality of life and symptoms. The five-year survival rate in the United States is around 65%. The individual likelihood of survival depends on how advanced the cancer is, whether or not all the cancer can be removed with surgery and the person's overall health. Globally, colorectal cancer is the third most common type of cancer, making up about 10% of all cases. In 2012, there were 1.4 million new cases and 694,000 deaths from the disease. It is more common in developed countries, where more than 65% of cases are found. It is less common in women than men.

More about Colorectal Cancer
Browse All Tags